Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluvastatin · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Fluvastatin | DRUG | - |
Inclusion Criteria: * Mixed dyslipidemia * Primary hypercholesterolemia Exclusion Criteria: * Pregnant or lactating women * Age \> 18 years Other protocol-defined inclusion and exclusion criteria may apply.
Fluvastatin is used for dyslipidemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia. It is a small molecule being developed by Novartis AG for cardiovascular conditions. It is currently in Phase 3 clinical development and is considered investigational, not yet approved.
Fluvastatin is a statin that works by inhibiting HMG-CoA reductase, the enzyme that controls the rate of cholesterol production in the liver. By blocking this enzyme, it reduces cholesterol synthesis, leading to lower levels of LDL cholesterol and triglycerides in the blood.
Fluvastatin is developed by Novartis AG, a multinational pharmaceutical company. The company is publicly traded under the ticker symbol NVS on the New York Stock Exchange. Novartis is conducting clinical trials to evaluate the drug's efficacy and safety.
Fluvastatin is in Phase 3 clinical development. It is an investigational drug and has not yet received FDA approval. The Phase 3 trials are completed, and the drug is being studied for its effects on lipid levels in patients with various cholesterol disorders.
Fluvastatin has been studied in several Phase 3 trials, including NCT00136799 in adults with mixed dyslipidemia or primary hypercholesterolemia, NCT00171236 in children with heterozygous familial hypercholesterolemia, and NCT00171288 comparing fluvastatin plus ezetimibe versus fluvastatin alone. All trials are completed.
Fluvastatin is also known by the brand name Lescol. It is a statin medication used to lower cholesterol. The drug is being developed by Novartis AG and is currently in Phase 3 trials for dyslipidemia and related conditions.